Despite a historical association with poor tolerability, a comprehensive review on safety of antileishmanial chemotherapies is lacking. We carried out an update of a previous systematic review of all published clinical trials in visceral leishmaniasis (VL) from 1980 to 2019 to document any reported ...serious adverse events (SAEs).
more
This Technical Brief reviews current practice and evidence on nutrition-specific preventive approaches to MAM, providing practical guidance for implementers and programme managers, and highlighting gaps in evidence and guidance.
This report presents examples from different agencies on how they approached community engagement in their Covid-19 responses, the tools and methodologies used, as well as the challenges they encountered and how they attempted to overcome these. It discusses what community engagement means to the va...rious agencies interviewed and in the literature consulted. And it puts forward some reflections on how CCCM and other sector agencies can take steps to ensure community participation in this and future pandemic responses.
more
No publication year indicated.
Non-discrimination disability and ethnic rights
Funded by CBM: www.cbm.org
Глобальная статистика свидетельствует о том, что бремя туберкулеза более актуально в городских регионах. Тем не менее, в тех странах, где большая часть населения п...оживает в сельской местности в условиях крайней нищеты, туберкулез является доминирующей проблемой среди сельских жителей. Бедность и ограниченный доступ к медицинским учреждениям и медицинским работникам значительно снижают способность людей с туберкулезом, проживающих в сельской местности, получить своевременную диагностику и лечение.
Accessed on 2019
more
Sci Rep. 2016; 6: 25920. Published online 2016 May 16. doi: 10.1038/srep25920
PLoS ONE 9(1): e87262. doi:10.1371/journal.pone.0087262
Key populations brief
Accessed 2017
СЕЛЬСКОЕ НАСЕЛЕНИЕ
ОСНОВНЫЕ ЗАТРОНУТЫЕ ГРУППЫ НАСЕЛЕНИЯ. КРАТКОЕ РУКОВОДСТВО.
PHARMA’S RESPONSE TO THE COVID-19 VACCINES CRISIS. Update Feb., 14, 2022. In September 2021, Amnesty International published A Double Dose of Inequality, which assessed the extent to which the pharmaceutical industry was restricting access to Covid-19 vaccines. This report updates that assessment ...of five leading vaccine manufacturers, AstraZeneca plc, BioNTech SE, Johnson & Johnson, Moderna Inc., and Pfizer Inc. It also includes for the first time an assessment of the two largest Chinese vaccine producers, China National Pharmaceutical Group Co., Ltd. (Sinopharm) and Sinovac Biotech Ltd. (Sinovac).
more